Drug Approval | December 16, 2021
U.S. FDA approves Bristol Myers Squibb’s Orencia
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
The data has been shared with the U.S.FDA as part of an ongoing rolling submission for Emergency Use Authorisation
Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
Intox is a GLP certified pre-clinical contract research organization with its test facilities in Pune
It accelerates the company’s vision for transforming healthcare and advancing patient care worldwide – from the hospital to the home
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
GCC Biotech is manufacturing the kits on a public-private partnership (PPP) model
Subscribe To Our Newsletter & Stay Updated
